144 related articles for article (PubMed ID: 37333166)
21. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
22. Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer.
Haque W; Verma V; Adeberg S; Rustomily R; Lo S; Butler EB; Teh BS
Rep Pract Oncol Radiother; 2021; 26(3):341-351. PubMed ID: 34277087
[TBL] [Abstract][Full Text] [Related]
23. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
Gao C; Wang F; Suki D; Strom E; Li J; Sawaya R; Hsu L; Raghavendra A; Tripathy D; Ibrahim NK
Int J Cancer; 2021 Feb; 148(4):961-970. PubMed ID: 32748402
[TBL] [Abstract][Full Text] [Related]
24. Activity of capecitabine for central nervous system metastases from breast cancer.
Gouveia MC; Hidalgo Filho CM; Moreno RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
[TBL] [Abstract][Full Text] [Related]
25. Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series.
Cosar R; Sut N; Ozen A; Tastekin E; Topaloglu S; Cicin I; Nurlu D; Ozler T; Demir S; Yıldız G; Şenödeyici E; Uzal MC
Breast Cancer (Dove Med Press); 2022; 14():259-280. PubMed ID: 36105268
[TBL] [Abstract][Full Text] [Related]
26. Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis.
Chen YR; Xu ZX; Jiang LX; Dong ZW; Yu PF; Zhang Z; Gu GL
World J Clin Oncol; 2023 Nov; 14(11):445-458. PubMed ID: 38059189
[TBL] [Abstract][Full Text] [Related]
27. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
[TBL] [Abstract][Full Text] [Related]
30. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials.
Buszek SM; Chung C
Front Oncol; 2019; 9():1224. PubMed ID: 31803614
[No Abstract] [Full Text] [Related]
32. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
33. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.
Nguyen A; Nguyen A; Dada OT; Desai PD; Ricci JC; Godbole NB; Pierre K; Lucke-Wold B
Curr Oncol; 2023 Jun; 30(6):5906-5931. PubMed ID: 37366925
[TBL] [Abstract][Full Text] [Related]
34. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
35. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
Zagouri F; Zoumpourlis P; Le Rhun E; Bartsch R; Zografos E; Apostolidou K; Dimopoulos MA; Preusser M
Cancer Treat Rev; 2020 Aug; 88():102046. PubMed ID: 32599393
[TBL] [Abstract][Full Text] [Related]
37. A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.
Prabhu RS; Turner BE; Asher AL; Marcrom SR; Fiveash JB; Foreman PM; Press RH; Patel KR; Curran WJ; Breen WG; Brown PD; Jethwa KR; Grills IS; Arden JD; Foster LM; Manning MA; Stern JD; Soltys SG; Burri SH
Neuro Oncol; 2019 Aug; 21(8):1049-1059. PubMed ID: 30828727
[TBL] [Abstract][Full Text] [Related]
38. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
Lamba N; Cagney DN; Catalano PJ; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Lin NU; Aizer AA; Tanguturi S
Neuro Oncol; 2023 May; 25(5):973-983. PubMed ID: 36367837
[TBL] [Abstract][Full Text] [Related]
39. Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center.
Kadi MS; Alhebshi AH; Shabkah AA; Alzahrani WA; Enani GN; Samkari AA; Iskanderani O; Saleem AM; Farsi AH; Trabulsi NH
Cureus; 2023 Jul; 15(7):e42389. PubMed ID: 37621828
[TBL] [Abstract][Full Text] [Related]
40. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
